Home  /  Outputs   /  JA3-WP4 (Page 2)

EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.

This is the assessment of the relative effectiveness of  ‘Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have

The final project plan of the assessment OTCA20 on “Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)” and the comments provided by external experts and the manufacturer are now available. OTCA20 Final Project Plan HERE OTCA20 External

We are pleased to announce that the collaborative rapid assessment, OTCA06, on “TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR THE TREATMENT OF PATIENTS AT INTERMEDIATE SURGICAL RISK” is available. The health technology assessed is a bioprothesis in the aortic valve deployed using

The final project plan of the assessment on “Bioresorbable Stents in cardiovascular indications (coronary artery disease)” and the comments provided by the external experts and the manufacturers are now available. OTCA16 Project Plan HERE OTCA16 External Expert and Manufacturer Comments HERE

We are pleased to announce that the joint rapid assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin” is available. The health technologies assessed include rtCGM